欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
本帖最后由 一沙一叶 于 2015-2-26 19:56 编辑
问题:在发给公司的警告信中,为什么FDA反对使用实际的样品来进行系统的稳定性测试(有时也称为“trial(试验)”、“test(测试)”或者“(prep预备)”运行)?
回答:FDA想要阻止“testing into compliance反复测试值到合格”的行为。在有些情况下,使用实际样品来进行系统适用性测试可能实际上是反复测试值到合格。 根据USP,系统适应性测试应该包括标准制剂或者其它标准溶液重复进样以确定精密度符合要求(参考USP通则<621>色谱法)。系统适应性测试,包括被进样的制剂的类别和选择的理由,都要按照公司确立的书面程序和适用的药典专论进行(§ 211.160)。 如果实际样品用来做系统适应性,那么它应当是被适当表征的次级标准品,并且要确立并遵循书面程序(§ 211.160 and 211.165)。所有的数据都应当保存在数据库中保留下来并用于审核,除非有书面的合理的理由。
In warning lettersto firms, why has FDA objected to the practice of using actual samples toperform system suitability testing (sometimes also referred to as “trial,”“test,” or “prep” runs)?
FDA wants todiscourage the practice of “testing into compliance.” In some situations,the use of actual samples to perform system suitability testing can be a meansof testing into compliance.
According to USP, system suitability tests should include replicateinjections of a standard preparation or other standard solutions to determineif requirements for precision are met (ref. USP General Chapter <621> Chromatography). Systemsuitability tests, including the identity of the preparation to be injected andthe rational for its selection, should be performed according to the firm’sestablished written procedures and the approved application or applicablecompendial monograph (§ 211.160).
If an actual sampleis to be used for system suitability, it should be a properly characterizedsecondary standard and written procedures should be established and followed (§211.160 and 211.165). All data should be included in the data set that isretained and subject to review unless there is documented scientificjustification for its exclusion.
|